Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649847 | 1.00 | KCNK3 (0.55) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL16053284 | 1.00 | KCNK3 (0.55) | KCNK3KCNK9JAK2JAK1GPR119 | |
| Hydrochloric Acid SCHEMBL6093599 | 0.99 | KCNK3 (0.54) | KCNK3KCNK9JAK2JAK1GPR119 | |
| Hydrochloric Acid SCHEMBL6095348 | 0.99 | KCNK3 (0.54) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL6609217 | 0.94 | KCNK3 (0.50) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL16376097 | 0.92 | KCNK3 (0.56) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL16963755 | 0.91 | JAK2 (0.56) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL3335624 | 0.91 | JAK2 (0.62) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL3642479 | 0.91 | JAK2 (0.56) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL6636263 | 0.89 | JAK2 (0.52) | KCNK3KCNK9JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | disclosed |
| WO-2005084667-A1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
| US-6858565-B2 | Thermosensitive recording material and novel color developer compounds | OJI PAPER CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20030040434-A1 | Thermosensitive recording material and novel color developer compounds | OJI PAPER CO., LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1264707-A2 | Thermosensitive recording material and novel color developer compounds | OJI PAPER CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | KCNK3 4019/4885KCNK9 3933/4885JAK2 268/4885 |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | KCNK3 129/4885KCNK9 130/4885JAK2 2087/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | KCNK3 1434/4885KCNK9 1786/4885JAK2 2711/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | KCNK3 1260/4885KCNK9 1495/4885JAK2 4094/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | KCNK3 1434/4885KCNK9 1786/4885JAK2 2711/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | KCNK3 4019/4885KCNK9 3933/4885JAK2 268/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | KCNK3 709/4885KCNK9 681/4885JAK2 4588/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | KCNK3 1434/4885KCNK9 1786/4885JAK2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.